4.8 Review

Development of autophagy inducers in clinical medicine

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 125, 期 1, 页码 14-24

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI73938

关键词

-

资金

  1. Cancer Prevention and Research Institute of Texas [RP120718-P1]
  2. NIH [R01CA84254, R01CA109618, U19AI109725]
  3. INSERM
  4. CNRS
  5. University Paris Descartes
  6. ANR
  7. INCa
  8. NATIONAL CANCER INSTITUTE [R01CA109618, R01CA084254] Funding Source: NIH RePORTER
  9. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI109725] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Defects in autophagy have been linked to a wide range of medical illnesses, including cancer as well as infectious, neurodegenerative, inflammatory, and metabolic diseases. These observations have led to the hypothesis that autophagy inducers may prevent or treat certain clinical conditions. Lifestyle and nutritional factors, such as exercise and caloric restriction, may exert their known health benefits through the autophagy pathway. Several currently available FDA-approved drugs have been shown to enhance autophagy, and this autophagy-enhancing action may be repurposed for use in novel clinical indications. The development of new drugs that are designed to be more selective inducers of autophagy function in target organs is expected to maximize clinical benefits while minimizing toxicity. This Review summarizes the rationale and current approaches for developing autophagy inducers in medicine, the factors to be considered in defining disease targets for such therapy, and the potential benefits of such treatment for human health.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据